GlassScriptPhysician profile
Leslie Erin Gilbert
NPI 1982838967
$8,247.79
in general payments reported to CMS, 2019-2025
25 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,108 · 2020: $138 · 2021: $125 · 2022: $604 · 2023: $4,136 · 2024: $440 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,362 · Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,361.93 |
| Food and Beverage | $1,910.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pierre Fabre Pharmaceuticals, INC. | $3,743.01 | 2023-2025 | Hemangeol |
| Abbott Laboratories | $1,754.78 | 2019-2022 | |
| Novo Nordisk INC | $719.09 | 2019-2025 | Alhemo |
| Csl Behring | $655.65 | 2019-2025 | Hemgenix |
| Genzyme Corporation | $354.88 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $239.62 | 2019-2024 | |
| Pfizer INC. | $141.37 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.68 | 2019-2025 | |
| Genentech, INC. | $86.51 | 2022-2025 | Hemlibra |
| Genentech USA, INC. | $85.91 | 2019-2025 | Hemlibra |
| Biomarin Pharmaceutical INC. | $85.23 | 2023 | Roctavian |
| Jazz Pharmaceuticals INC. | $51.53 | 2019 | |
| Adaptive Biotechnologies Corporation | $33.77 | 2025 | Clonoseq |
| Day One Biopharmaceuticals | $32.11 | 2025 | Ojemda |
| Kedrion Biopharma, INC. | $23.60 | 2024 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rare Disease Therapeutics, INC. | $18.60 | 2025 | Xromi |
| Alexion Pharmaceuticals, INC. | $18.41 | 2023 | Ultomiris |
| Duchesnay USA Incorporated | $17.37 | 2019 | |
| Y-Mabs Therapeutics, INC. | $17.18 | 2025 | Danyelza |
| Silvergate Pharmaceuticals, INC. | $17.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.47 | 2025 | Vonvendi |
| Mylan Institutional INC. | $12.76 | 2019 | |
| Emmaus Medical, INC. | $12.41 | 2019 | |
| Octapharma USA, INC. | $11.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.